Ann: NOX to Present Clinical Data at COSA Annual Meeting, page-11

DARRT-1 Results [8 August 2018]

The first 2 cohorts (400 mg and 800 mg) have completed their 12-week scans; in the 3rd cohort (1200 mg), only the first patient had reached his 6-week scan by the time of the meeting.

 In the 400 mg cohort, no patients are showing an abscopal response at 12-weeks.

 In the 800 mg cohort, 1 patient is showing a partial abscopal response at 12-weeks.

 In the 1200 mg cohort, the first patient in this cohort has reached the 6-week point. This patient is showing a partial abscopal response and with a halving of the PSA count suggestive of a significant decrease in tumour load.

Update 13 November 2018

Cohort 1 (400 mg Veyonda: 3 patients (Patients # 1-3) were assessed at 12 weeks as having stable disease by scan (RECIST assessment). At 24 weeks, Patients #1 and 3 remain stable on the basis of scans, while Patient # 2 has progressed.

Cohort 2 (800 mg): 1 patient (#7) was assessed at 12 weeks as having a partial response. At 24 weeks this patient continues to have a partial response including a strong decreasing PSA response.

Cohort 3 (1,200 mg): Patient #9 at 12 weeks continues to have a partial response and a strong decreasing PSA response.